1-19 of 19
Gerburg Wulf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3066: Fumarylacetoacetate hydrolase (FAH) stimulates resistance to CDK4/6 inhibitors in hormone receptor-positive breast cancer via a novel non-canonical function

Free
Jenny Hogstrom, Boryana Petrova, Hanna Doh, Camila Perea, Su Min Hong, Nina Kozlova, Kayla Cruz, Conor L. Evans, Jonah Lee, John Clohessy, Gerburg Wulf, Laura Collins, Naama Kanarek, Taru Muranen
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3066.
https://doi.org/10.1158/1538-7445.AM2025-3066
Published: 21 April 2025
View article titled, Abstract 3066: Fumarylacetoacetate hydrolase (FAH) stimulates resistance to CDK4/6 inhibitors in hormone receptor-positive breast cancer via a novel non-canonical function
Journal Articles

Abstract PO1-23-09: A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Free
Maxwell Lloyd, M Rosario Chica-Parrado, Todd Knepper, Chang-Ching Lin, Emily Podany, Christine Walko, Fabiana Napolitano, Caroline Weipert, Jiemin Liao, Arielle Medford, Lianne Ryan, Jennifer Keenan, Nicole Zhang, Shiyuan Liu, Gerburg Wulf, Katherine Clifton, Cynthia Ma, Hyo Han, Leif Ellisen, Aditya Bardia, Carlos Arteaga, Ariella Hanker, Seth Wander
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-23-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-23-09
Published: 02 May 2024
View article titled, Abstract PO1-23-09: A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Journal Articles

Abstract GS03-10: Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations

Free
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth Martin, Bryanna Nordern, Nicholas Chevalier, Ignaty Leshchiner, Anastasia Stavridi, Janice Kim, Alkistis Papatheodoridi, Hakan Gunaydin, Brian Danysh, Laxmi Parida, Ioannis Sanidas, Yongli Ji, Kayao Lau, Gerburg Wulf, Aditya Bardia, Laura Spring, Steven Isakoff, Jochen Lennerz, Levi Pierce, Ermira Pazolli, Gad Getz, Ryan Corcoran, Dejan Juric
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): GS03-10.
https://doi.org/10.1158/1538-7445.SABCS23-GS03-10
Published: 02 May 2024
View article titled, Abstract GS03-10: Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
Journal Articles

Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer

Free
Cynthia Ma, Jingqin Luo, Jessica Moss, Maryann Kwa, Ritesh Parajuli, Katia Khoury, Emily Douglas, Ashley Frith, Caron Rigden, Foluso Ademuyiwa, Shana Thomas, Brittney Haas, Gerburg Wulf, Claire Dees, Rabih Said
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS17-06.
https://doi.org/10.1158/1538-7445.SABCS23-PS17-06
Published: 02 May 2024
View article titled, Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
Journal Articles

Abstract CT042: NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations

Free
Timothy A. Yap, Ecaterina E. Dumbrava, Jordi Rodon Ahnert, Apostolia M. Tsimberidou, David Hong, Sarina A. Piha-Paul, Daniel D. Karp, Siqing Fu, Aung Naing, Paula Pohlmann, Jessica R. Rhudy, Sheila B. Berenji-Jalaei, Ashley A. Cole, Christian Valladolid, Desirae Dufner, Bruno B. Bockorny, Andrea Bullock, Daniel Fein, Elizabeth Buchbinder, Atish Choudhury, Candace Haddox, Elizabeth Lee, Gerburg Wulf, Percy Ivy, Rabih Said, Geoffrey Shapiro, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT042.
https://doi.org/10.1158/1538-7445.AM2024-CT042
Published: 05 April 2024
View article titled, Abstract CT042: NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
Journal Articles

Abstract 1222: Mechanisms of succinate-mediated drug resistance in ER+ breast cancer

Free
Jenny Hogstrom, Boryana Petrova, Camila Perea, Madelyn Ward, Gerburg Wulf, Laura Collins, Naama Kanarek, Taru Muranen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1222.
https://doi.org/10.1158/1538-7445.AM2024-1222
Published: 22 March 2024
View article titled, Abstract 1222: Mechanisms of succinate-mediated drug resistance in ER+ breast cancer
Journal Articles

Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial

Free
Kristina A. Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A. Boerner, Diane Durecki, Anne Noonan, Vandana Abramson, Cesar Santa-Maria, Hyo Han, Rita Nanda, Elizabeth Claire Dees, Haeseong Park, Saundra Buys, Namrata Peswani, Helen Chew, Hadeel Assad, Gerburg Wulf, Angelique Richardson, Meghna S. Trivedi, Adam Brufsky, James Abbruzzese, Anosheh Afghahi, Elad Sharon, Kurt Schalper, Patricia LoRusso
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT145.
https://doi.org/10.1158/1538-7445.AM2023-CT145
Published: 14 April 2023
View article titled, Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
Journal Articles

Abstract 1288: STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer

Free
Heta Jadhav, Constantia Pantelidou, Aditi Kothari, Renyan Liu, Gerburg Wulf, Jennifer L. Guerriero, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1288.
https://doi.org/10.1158/1538-7445.AM2022-1288
Published: 15 June 2022
View article titled, Abstract 1288: STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
Journal Articles

Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer

Free
Jonathan T Lei, Chen Huang, Ramakrishnan R Srinivasan, Suhas Vasaikar, Lacey E Dobrolecki, Alaina N Lewis, Christina Sallas, Susan G Hilsenbeck, C. Kent Osborne, Mothaffar F Rimawi, Matthew J Ellis, Varduhi Petrosyan, Alexander B Saltzman, Anna Malovannaya, Gerburg Wulf, Daniel C Kraushaar, Tao Wang, Xi Chen, Gloria V Echeverria, Meenakshi Anurag, Bing Zhang, Michael T Lewis
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-07-01.
https://doi.org/10.1158/1538-7445.SABCS21-P5-07-01
Published: 15 February 2022
View article titled, Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer
Journal Articles

Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance

Free
Jonathan T. Lei, Chen Huang, Ramakrishnan R. Srinivasan, Suhas Vasaikar, Lacey E. Dobrolecki, Alaina N. Lewis, Christina Sallas, Susan G. Hilsenbeck, C Kent Osborne, Mothaffar F. Rimawi, Matthew J. Ellis, Varduhi Petrosyan, Alexander B. Saltzman, Anna Malovannaya, Gerburg Wulf, Daniel C. Kraushaar, Tao Wang, Gloria V. Echeverria, Bing Zhang, Michael T. Lewis
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2992.
https://doi.org/10.1158/1538-7445.AM2021-2992
Published: 01 July 2021
View article titled, Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance
Journal Articles

Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC)

Free
Romualdo Barroso de Sousa, Nadim Ajami, Tanya E Keenan, Chelsea Andrews, Jessica L Pittenger, Gerburg Wulf, Laura Spring, Ian E Krop, Eric P Winer, Elizabeth A Mittendorf, Sara M Tolaney
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-09-16.
https://doi.org/10.1158/1538-7445.SABCS19-P3-09-16
Published: 15 February 2020
View article titled, Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC)
Journal Articles

Abstract 3858: Feasibility and efficacy of a precision treatment approach for triple-negative breast cancer in mouse models

Free
Hui Liu, Charles Murphy, Florian Karreth, Kangkang Yang, Gerburg Wulf, Lewis C. Cantley
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3858.
https://doi.org/10.1158/1538-7445.AM2016-3858
Published: 15 July 2016
View article titled, Abstract 3858: Feasibility and efficacy of a precision treatment approach for triple-negative breast cancer in mouse models
Journal Articles

Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort

Free
Ursula A. Matulonis, Gerburg Wulf, William Barry, Michael Birrer, Shannon Westin, Tatum Spagnoletti, Katherine Bell-McGuinn, Elizabeth Obermayer, Christin Whalen, Carol Aghajanian, David Solit, Gordon Mills, Lewis Cantley, Eric Winer
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT324.
https://doi.org/10.1158/1538-7445.AM2015-CT324
Published: 01 August 2015
View article titled, Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
Journal Articles

Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem–like Cell Traits in Breast Cancer

Free
Man-Li Luo, Chang Gong, Chun-Hau Chen, Daniel Y. Lee, Hai Hu, Pengyu Huang, Yandan Yao, Wenjun Guo, Ferenc Reinhardt, Gerburg Wulf, Judy Lieberman, Xiao Zhen Zhou, Erwei Song, Kun Ping Lu
Journal: Cancer Research
Cancer Res (2014) 74 (13): 3603–3616.
https://doi.org/10.1158/0008-5472.CAN-13-2785
Published: 30 June 2014
View article titled, Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem–like Cell Traits in Breast Cancer
Open the PDF for Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem–like Cell Traits in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 4781: EBV infection of mammary epithelial cells promotes malignant transformation.

Free
Hai Hu, Gerburg Wulf, Ashish Juvekar, Dirk P Dittmer, Joyce Fingeroth
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4781.
https://doi.org/10.1158/1538-7445.AM2013-4781
Published: 15 April 2013
View article titled, Abstract 4781: EBV infection of mammary epithelial cells promotes malignant transformation.
Journal Articles

Abstract 3339: HSP90 inhibitor 17-allylamino-geldanamycin enhances sensitivity to double-strand DNA break-inducing agents (platinum and PARP inhibitors) in epithelial ovarian cancer.

Free
Chiara Battelli, Alexander Morse, Hai Hu, Elena Levantini, Gerburg Wulf, Panagiotis A. Konstantinopoulos
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3339.
https://doi.org/10.1158/1538-7445.AM2013-3339
Published: 15 April 2013
View article titled, Abstract 3339: HSP90 inhibitor 17-allylamino-geldanamycin enhances sensitivity to double-strand DNA break-inducing agents (platinum and PARP inhibitors) in epithelial ovarian cancer.
Journal Articles

Abstract 3054: Expression of miR367* confers a “BRCAness” phenotype in epithelial ovarian cancer.

Free
Alexander Morse, Chiara Battelli, Hai Hu, Elena Levantini, Gerburg Wulf, Youngeun Choi, Dipanjan Chowdhury, Panagiotis Konstantinopoulos
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3054.
https://doi.org/10.1158/1538-7445.AM2013-3054
Published: 15 April 2013
View article titled, Abstract 3054: Expression of miR367* confers a “BRCAness” phenotype in epithelial ovarian cancer.
Journal Articles

Prolyl isomerase Pin1 as a potential treatment target in her2-positive breast cancer

Free
Prudence Lam, Bryan Wu, Erin Hofstatter, Mark Wotkowicz, Stephen Cannistra, Kun Ping Lu, Gerburg Wulf
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 842–843.
Published: 15 April 2006
View article titled, Prolyl isomerase Pin1 as a potential treatment target in her2-positive breast cancer
Journal Articles

The Prolyl Isomerase Pin1 Is a Novel Prognostic Marker in Human Prostate Cancer

Free
Gustavo Ayala, Dagong Wang, Gerburg Wulf, Anna Frolov, Rile Li, Janusz Sowadski, Thomas M. Wheeler, Kun Ping Lu, Lere Bao
Journal: Cancer Research
Cancer Res (2003) 63 (19): 6244–6251.
Published: 14 October 2003
View article titled, The Prolyl Isomerase Pin1 Is a Novel Prognostic Marker in Human Prostate Cancer
Open the PDF for The Prolyl Isomerase Pin1 Is a Novel Prognostic Marker in Human Prostate Cancer in another window